HMGB3 and bladder transitional cell carcinoma: Many studies have discovered a clear connection between the aberrant expression of HMGB3 and the incidence of various tumors, and HMGB3 is abundantly expressed in a variety of malignancies (including lung cancer, gastric cancer, bladder urothelial carcinoma, esophageal carcinoma and prostate adenocarcinoma) (5–8).